Key Points
- CFO Oluyemi Okupe sold 23,090 shares on Dec. 22 at an average price of $35.72 for about $824,775, leaving him with 94,333 shares — a 19.66% cut to his stake.
- This sale is part of a string of recent insider disposals (including an 85,000-share sale on Sept. 29 at $60.20 and multiple Oct/Nov transactions), generating millions in proceeds and indicating sustained insider selling activity.
- Company context: Hims & Hers missed quarterly EPS expectations ($0.06 vs. $0.09) but beat revenue ($599M), and its board has authorized a $250 million share buyback (about 3% of shares outstanding).
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 23,090 shares of the firm's stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $35.72, for a total value of $824,774.80. Following the completion of the transaction, the chief financial officer owned 94,333 shares of the company's stock, valued at approximately $3,369,574.76. This represents a 19.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Oluyemi Okupe also recently made the following trade(s):
- On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47.
- On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47.
- On Friday, October 17th, Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.13, for a total transaction of $662,250.96.
- On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.72, for a total transaction of $669,263.40.
- On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.20, for a total transaction of $5,117,000.00.
Hims & Hers Health Trading Down 0.7%
Shares of Hims & Hers Health stock opened at $34.79 on Wednesday. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The business has a 50 day moving average price of $41.06 and a 200 day moving average price of $48.17. The company has a market capitalization of $7.92 billion, a P/E ratio of 64.42, a P/E/G ratio of 6.93 and a beta of 2.41.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million for the quarter, compared to analysts' expectations of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business's quarterly revenue was up 49.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.32 EPS. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.
Hims & Hers Health declared that its board has initiated a share buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its shares are undervalued.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the company. Virtus Advisers LLC purchased a new stake in Hims & Hers Health during the second quarter valued at about $26,000. Quent Capital LLC acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $28,000. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the 3rd quarter worth about $28,000. Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health during the 2nd quarter worth approximately $29,000. Finally, Bessemer Group Inc. increased its position in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after purchasing an additional 312 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Hims & Hers Health in a research report on Monday. BTIG Research reiterated a "buy" rating and issued a $85.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. Canaccord Genuity Group restated a "buy" rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Barclays began coverage on Hims & Hers Health in a research note on Monday, December 8th. They issued an "overweight" rating and a $48.00 target price for the company. Finally, Wall Street Zen lowered Hims & Hers Health from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and an average price target of $45.50.
Read Our Latest Report on HIMS
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
